Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent

International Journal of Hematology

Volumn 82, Issue 5, 2005, Pages 445-448

  Takeshita, Akihiro ^a   Shinjo, Kaori ^a   Naito, Kensuke ^a   Matsui, Hirotaka ^a   Sahara, Naohi ^a   Shigeno, Kazuyuki ^a   Suzumura, Taeko ^a   Horii, Toshinobu ^a   Shirai, Naohito ^a   Maekawa, Masato ^a   Yada, Yoshihiro ^b   Teshima, Hirofumi ^b   Takeuchi, Jin ^c   Ohnishi, Kazunori ^a   Ohno, Ryuzo ^d  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Drug resistance; Gemtuzumab ozogamicin (Mylotarg)

Indexed keywords

CYTARABINE; DAUNORUBICIN; ENOCITABINE; GABEXATE MESILATE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; PREDNISOLONE; RETINOIC ACID; TAMIBAROTENE; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; GEMTUZUMAB; GLYCOPROTEIN P; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; HUMAN; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; REMISSION;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RECURRENCE; REMISSION INDUCTION; TRETINOIN;

EID: 33646460944     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05069     Document Type: Article

References (15)

1. Asou N, Adachi K, Tamura U, et al. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG). Cancer Chemother Pharmacol. 2001 ;48(suppl 1):S65-S71.
2. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003;17:1454-1463.
3. Douer D. New advances in the treatment of acute promyelocytic leukemia. Int J Hematol. 2002;76(suppl 2):179-187.
4. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("Mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222-4224.
5. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995-1999.
6. Paietta E, Andersen J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 1994;8:968-973.
7. Takeshita A, Shinjo K, Ohnishi K, Ohno R. Expression of multidrug resistance P-glycoprotein in myeloid progenitor lineage cells of different phenotype: similarities between normal and myeloid leukemia cells. Br J Haematol. 1996;93:18-21.
8. Takeshita A, Shinjo K, Naito K, et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia. 2005;19:1306-1311.
9. Takeshita A, Shibata Y, Shinjo K, et al. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. Ann Intern Med. 1996;124:893-896.
10. Ohno R, Kobayashi T, Morishima Y, et al. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG). Leukemia. 1992; 6(suppl 2):92-95.
11. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res. 2000;6:372-380.
12. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14:1436-1443.
13. Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002;16:813-819.
14. Takeshita A, Shinjo K, Naito K, et al. Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol. 2000;108:90-92.
15. 3-resistance in acute promyelocytic leukemia cells. Leukemia. 2003;17:648-650.